Experimental Allergic Encephalomyelitis (EAE)
Brain and spinal tissues were harvested from guinea pigs, wrapped in tin foil and placed in a freezer overnight. The following morning the tissue was thawed, weighed, and homog enized in sufficient one per cent phenol solution so that the final concentration was 40 per cent spinal tissue (by weight). The homogenate was then emulsified with an equal volume of adjuvant (4 mg of HKTB homogenized in 1 ml paraffin oil) by repeated drawings through a syringe fitted with an 18 gauge needle. The nerve emulsification was considered complete when a drop of the material no longer dispersed when placed in cold water. Five rats in each group were injected with 0.05 ml of the encephalitogenic emulsion.
Immediately after injecting the adjuvant or encephalitogenic emulsion subcutaneously into the left hind paw, the volumes of both hind paws were determined in a plethysmograph (9) . This period was designated as day 0 of the experiment. At various time intervals thereafter a group of these rats was used to measure changes in paw volume, then anesthetized, and blood withdrawn from the dorsal aorta to determine the erythrocyte sedimentation rate (ESR). These rats were sacrificed, the adrenals, thymus, and popliteal lymph nodes excised and wet weights recorded.
Preparation of Drugs
Both betamethasone and clonixin were suspended in carboxymethylcellulose solution and then administered orally each day before 10 a.m. The particular dose of each drug, betamethasone (1 mg/kg) and clonixin (60 mg/kg), was chosen because in prior experiments these respective doses were the lowest which consistently prevented joint inflammation without toxicity in the AAR. RESULTS 
Adjuvant Arthritic Rats (AAR)
In control rats adjuvant produced in the injected paw an inflammation within three hr. The volume of the injected paw did not increase further during the next ten days (Fig. 1) . At sometime between day 10 and 14 there was a secondary increase in paw size so that on day 21 the injected paw was almost twice the size it had been on day 10. The size of the contralateral hind paw did not change for the first 10 days and then increased steadily until day 21 (Fig. 2) .
Betamethasone decreased the inflammation in the adjuvant injected paw for the first 10 days and thereafter the swelling increased but not to the size of the adjuvant control rat paw (Fig. 1) . Betamethasone completely suppressed inflammation in the contralateral hind paw (Fig. 2) .
Clonixin inhibited the adjuvant-induced inflammation in the injected paw as well as the contralateral hind paw (Figs. 1 and 2 ). Clonixin differed somewhat from betametha sone by suppressing the inflammation of the injected-paw to a greater extent than the noninjected paw.
In adjuvant control rats increases in the ESR values paralleled increases in the size of the injected paw ( Table 1 ). The rise in ESR was seen three hr after adjuvant injection and reached peak levels by day 1. From day 1 through day 10 there was a decrease in the ESR level with a secondary increase from day 10 to day 21. Betamethasone did not prevent the initial increase in the ESR, but beginning on day 4 this steroid elicited a steady decline in the ESR until day 14 when the ESR was near normal levels. Clonixin had a marked effect on the ESR through out the entire 21 days of the experiment.
The popliteal lymph node draining the injected paw will be referred to as the injected node while the one draining the contralateral side will be called the non-injected node. In adjuvant control rats there was a continual increase in the weight of the injected node which reached a maximum on day 14 (Table 1) . There was slight decrease in weight between day 14 and day 21. There was no significant change in weight of the noninjected node until after day 10 at which time the node began to enlarge and on day 21 when it was four times the original weight. Betamethasone did not completely prevent injected node hypertrophy but did attenuate the response at all time periods. This steroid prevented the hypertrophy seen in the non injected nodes of adjuvant control rats and was most effective on day 21. Clonixin did not attenuate the hypertrophy seen in adjuvant control rats. In adjuvant control rats there was a steady increase in the weight of the adrenals from day 0 to day 21. Betamethasone caused the adrenals to atrophy while clonixin prevented to a degree the adrenal hypertrophy seen in the adjuvant control group.
In the adjuvant control group the thymus decreased in size at a steady rate throughout the experimental period. Betamethasone treatment increased the rate of thymolysis ob served in the adjuvant control rats. In contrast clonixin attenuated the thymolysis caused by adjuvant injection.
Experimental Allergic Encephalomyelitis (EAE)
In control rats paralysis did not appear until ten days after the injection of the enceph alitogenic emulsion. The clinical signs of the disease were maximal between days 14 and 21 when 100 per cent of the untreated challenged rats became paralyzed (Table 2) . Be tamethasone prevented paralysis in all rats except one. Clonixin did not alter the incidence of paralysis: all clonixin-treated rats were paralyzed by day 21.
The inflammation of the paw injected with encephalitogenic emulsion followed a pattern similar to that observed in the AAR but was not as severe ( Table 2 ). Betamethasone in hibited the swelling at all time periods. Clonixin appeared to have an effect similar to that of betamethasone except for day 14 when the injected paw volume was slightly greater than the injected paw volume of the adjuvant controls. The volume of the non-injected paw was not significantly increased in any of the experimental groups.
In control EAE rats (not given therapy) the ESR changes were general',y less than those seen in the AAR controls (Table 3 ). In untreated rats the ESR was elevated by day l , declining over the next 13 days with a slight secondary rise on day 21. Both betamethasone TABLE 2. Effect of daily oral doses of clonixin (60 mg/kg) and betamethasone (1 mg/ kg) on paw volumes and the incidence of paralysis at various times after an encephalitogenic challenge. and clonixin suppressed the ESR but as in the AAR clonixin had an earlier effect. In control EAE rats the injected node increased in weight for the first 10 days but with the first signs of paralysis the weight decreased ( Table 3 ). The effects of betamethasone and clonixin paralleled those observed in the AAR. No major weight changes occurred in the noninjected node in any group.
The changes in weight of the adrenal glands as well as the thymuses of EAE rats were similar to those observed in the AAR. In control EAE rats, the adrenals hypertrophied concomitant with thymolysis. Betamethasone caused an adrenal atrophy and accentuated the thymolytic process. The thymus weights of clonixin-treated rats followed a pattern similar to the EAE controls. DISCUSSION A comparison of the changes observed in the AAR and the EAE indicates there are many similarities in the models as well as some obvious differences. The injected paw in rats used in both studies follow a similar pattern : an immediate swelling (primary inflam mation) due to the injected material was followed by a secondary inflammation 10 days later. The biphasic increase in the ESR is a reflection of the primary and secondary inflam mation seen in both the AAR and EAE. The higher values of ESR in the AAR as compared to the EAE are due to the more severe inflammation seen in the AAR. Consistent with the inflammatory changes of the AAR and EAE are the similarities in the weight changes of the injected node in both models. The adrenal and thymus weights of rats used in the two models also followed similar patterns. The adrenal hypertrophy is probably a reflec tion of the stress which the rats were experiencing, while concomitant thymolysis is probably a result of the stress induced increase in adrenal steroid secretion (10).
In the EAE, paralysis occurs at about the same time that secondary inflammation begins in the noninjected hind paw. Both processes are thought to be caused by a delayed hyper sensitivity reaction to different antigens (11, 12) . It is surprising that in the EAE the in jected paw demonstrated secondary inflammation on day 10 while the noninjected paw did not. It is possible that the immobility of noninjected hind paws prevents proper circulation curtailing the movement of the proper complement of cells required for the inflammatory response. In contrast the injected paw has the necessary cellular elements in the area surrounding the primary inflammation and in the enlarged popliteal lymph node.
Betamethasone produced effects in the AAR and EAE similar to those reported for other corticoids (4) . The suppression of paw swelling in both AAR and EAE by betame thasone could be due to its anti-inflammatory activity (13) as well as its immunosuppres sive activity. The prevention of paralysis in the EAE by betamethasone could only be attributed to its immunosuppressive activity as other anti-inflammatory agents without immunosuppressive activity are inactive (5).
Clonixin could be classified as an anti-inflammatory agent without immunosuppressive activity because it affected only the paw swelling in both the AAR and EAE but did not prevent paralysis in the latter model.
There are different effects of betamethasone and clonixin in the ESR. The rate at which the red blood cells (RBC) fail in the plasma is dependent upon the rate at which the RBC's aggregate and the density of the plasma (14) . Nonsteroidal anti-inflammatory drugs like clonixin have been reported to inhibit aggregation of BBC's while corticoids do not (15) . These observations may serve to explain the rapid and marked effect of clonixin on the ESR. Since betamethasone would not be expected to affect RBC aggregation it can be assumed that suppression of the secondary rise in the ESR by betamethasone is due to preventing changes in plasma protein concentration caused by the inflammation. The anti-inflammatory properties of clonixin could also contribute to preventing the ESR increase, especially during the secondary phase.
Betamethasone has a marked lympholytic effect while clonixin was without obvious effect on lymphoid tissue. This may be one of the immunosuppressive actions of betametha sone. Although clonixin had no effect on the popliteal lymph node weights, it did at tenuate the thymolysis in the AAR. The decreased thymolysis in the clonixin-treated rats is a reflection of decreased stress (probably due to less pain) as a results of the anti inflammatory and analgesic properties of the drug (6) . The lack of antiparalytic activity in the EAE would rule out clonixin preventing stress-induced thymolysis in this model. It can be concluded from this study that clonixin is an effective anti-inflammatory drug with no immunosuppressive properties.
SUMMARY
Clonixin and betamethasone inhibited polyarthritis induced by administering complete Freund's adjuvant in rats. The anti-inflammatory activity of these agents in probably brought about by different mechanisms as demonstrated by their respective effects on the popliteal lymph nodes and the erythrocyte sedimentation rate (ESR). Clonixin did not prevent hypertrophy of the lymph nodes in adjuvant-treated rats whereas betamethasone did. Clonixin suppressed the ESR at an earlier stage of the disease than did betamethasone. The analgesic and anti-inflammatory action of clonixin decreases the stress experienced by adjuvant arthritic rats (AAR) as demonstrated by a decrease in adrenal hypertrophy and thymolysis.
In experimental allergic encephalomyelitis (EAE) clonixin inhibited hind paw inflam mation as in the AAR but did not prevent paralysis. Betamethasone inhibited the inflam mation and the paralysis in EAE.
